secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0000879169-25-000053
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q1 2025 revenues up 20% to $1.05B; Jakafi guidance raised
----------------------------------------------------------------

- Total revenues $1,053M (+20% YoY); product rev $922M (+26%); GAAP diluted EPS $0.80; Non-GAAP $1.16.
- Jakafi net product rev $709M (+24%); full-year 2025 guidance raised to $2,950-$3,000M.
- Opzelura net rev $119M (+38%); Niktimvo launch rev $14M in first two months.
- Povorcitinib meets primary endpoints in Phase 3 HS and Phase 2 CSU; supports regulatory submission.
- Cash and marketable securities $2.4B; pipeline progress across MPN, oncology, and IAI programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916925000053/0000879169-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916925000053/incy-20250429.htm
  HTML page:      https://secwatch.observer/filing/0000879169-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer